Antibody-Drug Conjugates
•40 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (40)
| Company | Market Cap | Price |
|---|---|---|
|
LLY
Eli Lilly and Company
Antibody-drug conjugates are part of Lilly's oncology strategy.
|
$816.66B |
$863.11
+2.20%
|
|
JNJ
Johnson & Johnson
DARZALEX is an antibody-drug conjugate, a major monoclonal antibody-based oncology modality.
|
$454.86B |
$188.88
-0.09%
|
|
ABBV
AbbVie Inc.
Elahere is an antibody-drug conjugate, representing AbbVie’s ADC oncology modality.
|
$385.15B |
$218.07
-4.44%
|
|
AZN
AstraZeneca PLC
Antibody-Drug Conjugates are a core modality in AZN's cancer therapy portfolio.
|
$255.44B |
$82.39
+0.06%
|
|
MRK
Merck & Co., Inc.
Merck is advancing antibody-drug conjugates (ADCs) through collaborations, a distinct oncology modality.
|
$215.90B |
$85.99
-0.34%
|
|
GILD
Gilead Sciences, Inc.
Trodelvy is a TROP2-targeted antibody-drug conjugate (ADC), a core oncology modality.
|
$149.01B |
$119.77
+1.12%
|
|
PFE
Pfizer Inc.
Pfizer employs Antibody-Drug Conjugates (ADC) as a key oncology modality, reinforced by the Seagen acquisition and pipeline assets like Padcev.
|
$140.14B |
$24.66
+1.50%
|
|
ONC
BeOne Medicines Ltd.
BG-C9074 is an antibody-drug conjugate (ADC) asset within the solid tumor program.
|
$33.55B |
$310.56
+0.76%
|
|
GMAB
Genmab A/S
Genmab's marketed therapies include antibody-drug conjugates (ADC) such as Rina-S and Tivdak, qualifying the Antibody-Drug Conjugates category.
|
$18.93B |
$28.60
-0.24%
|
|
EXEL
Exelixis, Inc.
XB010 and XB371 are antibody-drug conjugates developed by Exelixis.
|
$10.55B |
$38.67
-0.69%
|
|
RNA
Avidity Biosciences, Inc.
Antibody-Drug Conjugates: antibody-oligonucleotide conjugate approach analogous to ADC modality.
|
$8.42B |
$69.83
+0.20%
|
|
MRUS
Merus N.V.
ADCs capability via ADClonics platform, enabling antibody-drug conjugates (Biohaven collaboration).
|
$6.57B |
$94.86
-0.21%
|
|
ZLAB
Zai Lab Limited
Active antibody-drug conjugate (ADC) development including DLL3 and LRRC15 ADC programs.
|
$2.83B |
$26.12
+2.37%
|
|
IDYA
IDEAYA Biosciences, Inc.
Develops Antibody-Drug Conjugates (e.g., IDE849 DLL3 ADC) for cancer treatment.
|
$2.79B |
$31.87
+0.85%
|
|
BHVN
Biohaven Ltd.
BHV-1510 is a next-generation Antibody Drug Conjugate (ADC) targeting Trop2, a key oncology modality.
|
$1.76B |
$17.20
-1.06%
|
|
IMNM
Immunome, Inc.
Primary modality across the pipeline is Antibody-Drug Conjugates (ADCs).
|
$1.40B |
$16.08
+0.63%
|
|
ZYME
Zymeworks Inc.
Lead ADC programs leverage proprietary antibody-drug conjugate platforms with a defined payload.
|
$1.33B |
$19.07
-0.26%
|
|
DAWN
Day One Biopharmaceuticals, Inc.
DAY301 is an Antibody-Drug Conjugate (PTK7-targeted) under development, a core modality for this company.
|
$754.14M |
$7.43
+5.54%
|
|
FLGT
Fulgent Genetics, Inc.
Development of Antibody-Drug Conjugates in oncology.
|
$683.46M |
$22.44
-0.62%
|
|
AVBP
ArriVent BioPharma, Inc. Common Stock
Pipeline includes ARR-217, an antibody-drug conjugate (ADC) program for GI cancers.
|
$640.80M |
$18.73
+1.38%
|
|
ADCT
ADC Therapeutics S.A.
ADCT's lead product ZYNLONTA is an antibody-drug conjugate (ADC), directly aligning with the Antibody-Drug Conjugates category.
|
$442.34M |
$4.45
-3.89%
|
|
CTMX
CytomX Therapeutics, Inc.
CX-2051 is a lead antibody-drug conjugate (ADC) using the PROBODY platform, making Antibody-Drug Conjugates the direct product category.
|
$287.82M |
$3.57
+7.21%
|
|
PYXS
Pyxis Oncology, Inc.
MICVO is an antibody-drug conjugate (ADC), the core modality Pyxis is developing.
|
$220.53M |
$3.57
+4.39%
|
|
IPHA
Innate Pharma S.A.
IPH4502 is a proprietary Antibody-Drug Conjugate (ADC), a direct product category the company is developing.
|
$159.51M |
$1.97
-1.26%
|
|
CRBP
Corbus Pharmaceuticals Holdings, Inc.
CRB-701 is a next-generation antibody-drug conjugate targeting Nectin-4, a major ADC modality.
|
$148.68M |
$12.06
-26.64%
|
|
MGNX
MacroGenics, Inc.
Pipeline includes antibody-drug conjugates (MGC026, MGC028, vobra duo) using a TOP1i payload.
|
$104.73M |
$1.65
+3.45%
|
|
STRO
Sutro Biopharma, Inc.
Directly represents Sutro's core assets: Antibody-Drug Conjugates (ADC) programs using the XpressCF+ platform.
|
$94.60M |
$1.11
-3.88%
|
|
PRLD
Prelude Therapeutics Incorporated
The company is developing precision antibody-drug conjugates (pADCs) in collaboration with AbCellera, a direct ADC product/category.
|
$89.77M |
$1.59
+1.27%
|
|
ALXO
ALX Oncology Holdings Inc.
ALX2004 is described as an EGFR-targeted antibody-drug conjugate, which fits the Antibody-Drug Conjugates category.
|
$82.30M |
$1.54
-0.32%
|
|
ADAG
Adagene Inc.
Antibody-Drug Conjugates (ADCs) collaboration and development via masked antibodies.
|
$78.80M |
$1.78
-7.29%
|
|
OSTX
OS Therapies Incorporated
OST-tADC represents antibody-drug conjugate platform technology leveraging tunable linkers.
|
$52.26M |
$1.83
+3.67%
|
|
MRSN
Mersana Therapeutics, Inc.
Emi-Le (XMT-1660) is an antibody-drug conjugate (ADC), the direct product category the company develops.
|
$47.76M |
$9.68
+4.03%
|
|
FGEN
FibroGen, Inc.
FG-3246 is an antibody-drug conjugate (ADC), a major investable category.
|
$44.94M |
$11.12
+0.72%
|
|
ATNM
Actinium Pharmaceuticals, Inc.
Antibody-based therapeutics with cytotoxic payloads align with antibody-drug conjugate-like approaches, including radioconjugates.
|
$44.61M |
$1.42
|
|
LTRN
Lantern Pharma Inc.
Lantern's ADC program (cryptophycin ADC) positions it in the Antibody-Drug Conjugates modality.
|
$43.25M |
$4.01
+1.01%
|
|
BCAB
BioAtla, Inc.
Oz-V and Mec-V are ADCs (CAB-ROR2-ADC, CAB-AXL-ADC) - major product modality.
|
$40.86M |
$0.70
+0.60%
|
|
AKTX
Akari Therapeutics, Plc
Core product category: antibody-drug conjugates (ADC) platform and lead AKTX-101 using PH1 payload targeting Trop2.
|
$37.14M |
$0.76
+4.07%
|
|
NXTC
NextCure, Inc.
NextCure's lead programs are Antibody-Drug Conjugates (ADCs), the core product modality of the company.
|
$29.45M |
$12.62
+2.98%
|
|
BOLT
Bolt Biotherapeutics, Inc.
Bolt's ISACs are antibody-conjugate constructs with immune-stimulatory payloads, aligning with Antibody-Drug Conjugates as a therapeutic modality.
|
$11.04M |
$5.80
+1.21%
|
|
CBIO
Crescent Biopharma, Inc.
CR-002 and CR-003 are antibody-drug conjugates (ADCs) with topoisomerase inhibitor payloads.
|
$8.23M |
$12.79
+2.24%
|
Loading company comparison...
Loading industry trends...
Loading research report...
